Background: This guideline addresses the diagnosis of hypersensitivity pneumonitis (HP). It
represents a collaborative effort among the American Thoracic Society, Japanese …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on which …

Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Pulmonary fibrosis is the end stage of many diffuse parenchymal lung diseases. It is
characterised by excessive matrix formation leading to destruction of the normal lung architecture …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Background Steroids remain the first-choice therapeutic in sarcoidosis; however, long-term
use is associated with toxicity. Evidence defining the best second-line therapeutic is currently …

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung
disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic …

Importance There is a major need for effective, well-tolerated treatments for idiopathic
pulmonary fibrosis (IPF). Objective To assess the efficacy and safety of the autotaxin inhibitor …

Background Idiopathic interstitial pneumonias are often complicated by pulmonary hypertension,
increasing morbidity and mortality. There are no approved treatments for pulmonary …

Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis
have established that pirfenidone and nintedanib prevent about 50% of the decline in forced …